Sign In
Buy IMCR
$29.20
-0.150 (-0.511%)
At Close: Jun 23, 2026
Immunocore to present at upcoming investor conferences
04:00pm, Thursday, 04'th Apr 2024
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio
11:07am, Wednesday, 13'th Mar 2024
Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest.
Immunocore presented two posters at CROI 2024
04:30pm, Tuesday, 05'th Mar 2024
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore to present at upcoming investor conferences
07:00am, Friday, 01'st Mar 2024
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
10:57am, Wednesday, 28'th Feb 2024
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
07:34am, Wednesday, 28'th Feb 2024
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increa
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
07:00am, Wednesday, 21'st Feb 2024
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
5 Biotech Stocks to Consider for Your Portfolio in 2024
10:00am, Tuesday, 13'th Feb 2024
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR,
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
06:20am, Thursday, 01'st Feb 2024
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movin
Immunocore Prices Upsized Convertible Senior Notes Offering
11:30pm, Tuesday, 30'th Jan 2024
Immunocore Prices Upsized Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 30, 2024) Immunocore Holdings plc (Nasdaq: IMCR) today announced the pr
Immunocore Announces Proposed Convertible Senior Notes Offering
04:05pm, Monday, 29'th Jan 2024
Immunocore Announces Proposed Convertible Senior Notes Offering (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, January 29, 2024) Immunocore Holdings plc (Nasdaq: IMCR), today announced i
Should You Buy Immunocore Holdings PLC Sponsored ADR (IMCR) After Golden Cross?
11:19am, Wednesday, 10'th Jan 2024
From a technical perspective, Immunocore Holdings PLC Sponsored ADR (IMCR) is looking like an interesting pick, as it just reached a key level of support. IMCR's 50-day simple moving average crossed a
Best Momentum Stocks to Buy for January 10th
11:19am, Wednesday, 10'th Jan 2024
IMCR, CPRX and AMPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 10, 2024.
New Strong Buy Stocks for January 10th
07:31am, Wednesday, 10'th Jan 2024
PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.
